Synthesis, characterization of ruthenium (III) macrocyclic complexes of 1, 4, 8, 11-tetraazacyclotetradecane(cyclam) and in vitro assessment of anti-cancer activity. (2022)

• Record Type: Journal Article
• Authors: Kanaoujiya, Rahul; Singh, Dharmveer; Minocha, Tarun; Yadav, Sanjeev Kumar; Srivastava, Shekhar
• Is Part Of: Materials today. Volume 65:Part 8(2022)
• Page Start: 3143
• Page End: 3149
• Publication Date: 2022
• Subjects: Ruthenium -- Macrocyclic ligand -- X-ray photoelectron spectroscopy -- Cervical cancer -- Proliferation and apoptosis; Materials science -- Congresses -- Periodicals; 620.1
• DOI: 10.1016/j.matpr.2022.05.354
• Languages: English
• ISSNs: 2214-7853

Abstract

Abstract: Cervical cancer is the fourth prevalent malignancy associated with cancer related deaths worldwide. A variety of resources has been invested in its treatment but the overall results are still unsatisfactory. During the last couple of years, a myriad of studies has inflamed the interest of macrocyclic ligands against a variety of chronic diseases. Macrocyclic ligands are pertinent because of their own attribution transient to the transition metal complexes. In this study noble macrocyclic ligand complexes of ruthenium (III) have been synthesized [RuCl3 L 1 ](Where L 1 = 1, 4, 8, 11-tetraazacyclotetradecane) and evaluated for the characterization. Cyclam macrocyclic ligand was used and its complexation properties with ruthenium (III) metal were investigated by elemental analysis, molar conductivity, FTIR, and XPS. Spectroscopic studies revealed distorted octahedral geometry of complexes. Moreover, the synthesized noble ruthenium cyclam complexes were executed for in vitro assessment to examine the anti-cancer attribute and results suggested that the ruthenium cyclam complex inhibits proliferation and induces apoptosis in cervical cancer SiHa cells.